Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review.

摘要: A 2008 review by our group concluded that the risk of neuropsychiatric adverse events (NPAEs) in influenza patients was not increased oseltamivir exposure, and did identify any mechanism which or its metabolites could cause worsen such events. The current article reviews new information on this topic. Between September 16, 2007 May 15, 2010, 1,805 spontaneously-reported NPAEs were identified 1,330 receiving oseltamivir: 767 (42.5%) from Japan, 296 (16.4%) USA, 742 (41.1%) other countries. more common children: 1,072 (59.4%) those aged ≤16 years. often occurred within 48 h treatment initiation (953 events; 52.8%). Nearly half serious nature (838; 46.4%). three largest categories abnormal behavior (457 events, 25.3%), miscellaneous psychiatric (370; 20.5%), delusions/perceptual disturbances (316 17.5%). total 1,545 (85.6%) eight different considered to be delirium delirium-like. Twenty-eight suicide-related reported. US healthcare claims database analysis showed 7,798 oseltamivir-treated no higher than 10,411 antivirals, but a study Japan less conclusive. NPAE frequency oseltamivir-exposed Japanese Taiwanese children with same as unexposed children. New UK General Practice Research Database relative adjusted 2.18-times general population. Other epidemiology studies report frequent occurrence encephalitis similar disorders independently exposure. data support findings original assessment. Evidence suggests influenza-related encephalopathies are caused influenza-induced inflammatory responses, work is needed confirm underlying mechanisms.